Table 1.
Patient and disease characteristics before first cycle of R-CHOP
| Characteristic | Overall N = 234 |
G-CSF type in cycle 1 | ||
|---|---|---|---|---|
| No G-CSF administration n = 60 |
Daily G-CSF n = 122 |
Pegfilgrastim n = 52 |
||
| Sex | ||||
| Male | 110 (47.0) | 35 (58.3) | 53 (43.4) | 22 (42.3) |
| Female | 124 (53.0) | 25 (41.7) | 69 (56.6) | 30 (57.7) |
| Age, years; mean (SD) | 63.7 (12.7) | 57.6 (12.8) | 64.4 (11.1) | 69.1 (13.3) |
| < 65 | 114 (48.7) | 41 (68.3) | 54 (44.3) | 19 (36.5) |
| 65 to < 80 | 97 (41.5) | 17 (28.3) | 61 (50.0) | 19 (36.5) |
| ≥ 80 | 23 (9.8) | 2 (3.3) | 7 (5.7) | 14 (26.9) |
| BMI, kg/m2; mean (SD) | 22.6 (3.4) | 23.4 (3.7) | 22.5 (3.5) | 21.9 (2.7) |
| Albumin, g/dL; mean (SD) | 3.8 (0.6) | 4.0 (0.5) | 3.8 (0.6) | 3.7 (0.6) |
| Total bilirubin, mg/dL; mean (SD) | 0.6 (0.3) | 0.5 (0.2) | 0.6 (0.3) | 0.5 (0.3) |
| Hemoglobin, g/dL; mean (SD) | 12.5 (2.0) | 13.1 (1.9) | 12.5 (1.7) | 11.9 (2.4) |
| ANC, cells/μL; mean (SD) | 4176.1 (1979.6) | 4147.7 (1425.1) | 4246.5 (2286.0) | 4043.8 (1767.7) |
| ALC, cells/μL; mean (SD) | 1379.3 (1366.9) | 1756.0 (2148.5) | 1255.7 (1051.5) | 1234.6 (590.1) |
| Relative dose intensity, %; mean (SD) | 88.9 (12.4) | 91.1 (13.4) | 89.7 (10.8) | 84.5 (14.0) |
| Performance status | ||||
| 0–1 | 224 (95.7) | 59 (98.3) | 117 (95.9) | 48 (92.3) |
| 2–4 | 10 (4.3) | 1 (1.7) | 5 (4.1) | 4 (7.7) |
| Diagnosis | ||||
| DLBCL | 158 (67.5) | 32 (53.3) | 84 (68.9) | 42 (80.8) |
| FL | 40 (17.1) | 16 (26.7) | 20 (16.4) | 4 (7.7) |
| Transformed DLBCL | 13 (5.6) | 5 (8.3) | 5 (4.1) | 3 (5.8) |
| Othera | 23 (9.8) | 7 (11.7) | 13 (10.7) | 3 (5.8) |
| Stage | ||||
| I–II | 107 (45.7) | 34 (56.7) | 52 (42.6) | 21 (40.4) |
| III–IV | 127 (54.3) | 26 (43.3) | 70 (57.4) | 31 (59.6) |
| Bone marrow involvement | ||||
| No | 206 (88.0) | 52 (86.7) | 107 (87.7) | 47 (90.4) |
| Yes | 28 (12.0) | 8 (13.3) | 15 (12.3) | 5 (9.6) |
| Complications (diabetes) | ||||
| No | 213 (91.0) | 53 (88.3) | 111 (91.0) | 49 (94.2) |
| Yes | 21 (9.0) | 7 (11.7) | 11 (9.0) | 3 (5.8) |
| Complications (liver/kidney disease) | ||||
| No | 222 (94.9) | 57 (95.0) | 118 (96.7) | 47 (90.4) |
| Yes | 12 (5.1) | 3 (5.0) | 4 (3.3) | 5 (9.6) |
| Other complicationsb | ||||
| No | 110 (47.0) | 29 (48.3) | 61 (50.0) | 20 (38.5) |
| Yes | 124 (53.0) | 31 (51.7) | 61 (50.0) | 32 (61.5) |
Data are given as n (%) unless otherwise stated
ALC absolute lymphocyte count, ANC absolute neutrophil count, BMI body mass index, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, G-CSF granulocyte colony-stimulating factor, PS performance status
aOthers included mucosa-associated lymphoid tissue lymphoma, mantle cell lymphoma, and B-cell lymphoma
bOther complications included hypertension, hyperlipidemia, dyslipidemia, abnormal glucose tolerance, and hyperuricemia and only accounted for those that were present in ≥ 5 patients